Tvardi Therapeutics TVRD 深 滬
等待開盤 09-17 09:30:00 美东时间
1.73
-0.030
-1.70%
華盛通- 最 高1.805
- 今 開1.74
- 成交量 12.67万股
- 最 低 1.73
- 昨 收 1.76
- 總市值 2307.64万
- 52周最高 43.65
- 市盈率 靜 --
- 換手率 0.95%
- 52周最低 1.50
- 委 比 79.28%
- 總股本 1333.89万
- 歷史最高 1067.292
- 量 比 1.09
- 振 幅 4.26%
- 歷史最低 1.50
- 每 手 1
- 風險率 9.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology launched Caspian Therapeutics, a separately financed subsidiary focused on developing small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian secured $50 million in financing led by BVF Partners, with participation from T1D Fund, Eli Lilly, and others. The company will advance KO-7246, a next-generation menin inhibitor, through clinical proof of concept. Preclinical studies demonstrate KO-7246's potential ...
09-09 11:00
Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics announced its participation in upcoming investor events: the Wells Fargo 21st Annual Healthcare Conference on September 9 in Boston, the 2026 Cantor Global Healthcare Conference on September 10 in New York, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14 in New York. The company focuses on developing oral STAT3 inhibitors for inflammatory and proliferative diseases. TTI-109, a prodrug of TTI-10...
08-26 12:00
Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent. This is a 31 percent increase over losses of $(1.00) per share from the same period last year.
08-14 19:07
Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UC
Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it will host a KOL webinar on Wed...
08-12 20:04
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5
BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $15 to $5.
07-31 03:05
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
美股夜盘 | Republic Power涨38.76%，巨龙在线涨22.55%
Tvardi Therapeutics Inc.涨-10.80%；Dreamland涨-9.80%；有信科技涨-9.33%
07-09 08:05
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target
BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $15 price target.
07-08 00:57
